Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer

por Dómine Gómez, Manuel, Csőszi, Tibor, Jaal, Jana, Kudaba, Iveta, Nikolov, Krasimir, Radosavljevic, Davorin, Xiao, Jie, Horton, Janet K., Malik, Rajesh K., Subramanian, Janakiraman
Publicado 2021

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCL...

por Lai, Anne Y, Sorrentino, Jessica A, Dragnev, Konstantin H, Weiss, Jared M, Owonikoko, Taofeek K, Rytlewski, Julie A, Hood, Jill, Yang, Zhao, Malik, Rajesh K, Strum, Jay C, Roberts, Patrick J
Publicado 2020

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analy...

por Ferrarotto, Renata, Anderson, Ian, Medgyasszay, Balazs, García‐Campelo, Maria Rosario, Edenfield, William, Feinstein, Trevor M., Johnson, Jennifer M., Kalmadi, Sujith, Lammers, Philip E., Sanchez‐Hernandez, Alfredo, Pritchett, Yili, Morris, Shannon R., Malik, Rajesh K., Csőszi, Tibor
Publicado 2021

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung...

por Li, Chao, Hart, Lowell, Owonikoko, Taofeek K., Aljumaily, Raid, Rocha Lima, Caio Max, Conkling, Paul R., Webb, Roy Timothy, Jotte, Robert M., Schuster, Steven, Edenfield, William J., Smith, Deborah A., Sale, Mark, Roberts, Patrick J., Malik, Rajesh K., Sorrentino, Jessica A.
Publicado 2021